CRISPR In Vivo: The End of Artisanal Medicine and the Dawn of Industrialized Cures

The 2025 first-in-human in vivo CRISPR therapy marks a historic pivot from laboratory novelty to mass-scale clinical reality, fundamentally reshaping precision medicine. This transition heralds the industrialization of personalized treatments, enabling functional cures for genetic disorders and cancers while challenging global healthcare economics and equity frameworks.